Hunan Cancer Hospital

Preclinical characterization and first-in-human phase I dose-escalation results with JYB1907, a novel anti-GARP-TGF-β1 complex monoclonal antibody in patients with advanced solid tumors

Transforming growth factor-β1 (TGF-β1) promotes immunosuppression in the tumor microenvironment via the GARP-latent TGF-β1 complex on regulatory T cells. JYB1907 is a humanized IgG4 monoclonal antibody targeting this complex. Preclinically, JYB1907 bound GARP-latent TGF-β1 comple...

Multi-cell death gene signature predicts lung adenocarcinoma prognosis and reveals FURIN regulates ferroptosis via NRF2-xCT-GPX4 axis

FURIN, a proprotein convertase, has been implicated in tumor progression. Nevertheless, how it contributes to lung adenocarcinoma (LUAD) and ferroptosis is still not well understood. We investigated FURIN expression and its prognostic value using the TCGA-LUAD cohort, CPTAC, and...

The Executioners of Mitochondrial Apoptosis: Structures, Mechanisms, and Therapeutic Advances of BAX, BAK, and BOK

ABSTRACT The BCL‐2 family effector proteins BAX, BAK, and BOK are pivotal regulators of the mitochondrial apoptosis pathway. They act as the ultimate executioners responsible for the irreversible step of mitochondrial outer membrane permeabilization. Their molecular conformations...

A dual-tower multimodal framework with feature quality enhancement for predicting pathological complete response after neoadjuvant chemotherapy in breast cancer: a multicenter study

BACKGROUND: Pathological complete response (pCR) is a key endpoint following neoadjuvant chemotherapy (NAC) in breast cancer, with potential to guide treatment adaptation and surgical de-escalation. However, limited generalizability across institutions remains a major challenge d...

Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China

Abstract Purpose Approximately 30% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) cases are categorized as low-risk by the international prognostic index (IPI). Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has demonstrated e...

Neural–tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies

Neural-tumor crosstalk has emerged as a critical frontier in tumor microenvironment research. Central to this field is the dynamic, bidirectional regulatory network between the nervous system and tumor cells that orchestrates malignant progression. This review focuses on tumors a...

Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence

The absence of accurate, noninvasive, scalable screening tools keeps early esophageal cancer (EC) detection a global health challenge. Although noncontrast computed tomography (NC CT) is widely accessible, the esophagus is a hollow tubular structure prone to collapse and motion a...

Fibroblast-associated migrasome programs define TSPAN4-driven progression and clinical risk stratification in gastric cancer

Gastric cancer (GC) is a highly aggressive malignancy with poor prognosis, characterized by complex tumor microenvironment (TME) interactions. Migrasomes have been implicated in cancer progression, but their specific roles and spatial correlation in GC remain unclear. Using 10x G...

Precision Selection for Targeted Radionuclide Therapy in Prostate Cancer: Biparametric MRI Radiomics Combined with Serum Bone Turnover Biomarkers for Predicting Postoperative Bone Metastasis

Objective: Particularly for patients with bone-dominant illness, targeted radionuclide treatments are becoming a viable treatment option for metastatic prostate cancer (PCa). Precision treatment selection and improved therapeutic outcomes may result from early detection of patien...

CT-Derived Body Composition and Early Changes Predict Outcomes of First-Line Chemo-Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Abstract Background Reliable biomarkers for risk stratification and treatment monitoring in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) treated with first-line chemo-immunotherapy remain limited. This study evaluated the prognostic value of baseline computed tomograph...

Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer

IMPORTANCE The combination of neoadjuvant taxanes with trastuzumab and pertuzumab remains the cornerstone treatment strategy in ERBB2 -positive breast cancer. Anbenitamab (a ERBB2 -biparatopic antibody that induces profound receptor clustering) and HB1801 (a solvent-free albumin-...

A Pan‐Cancer Single‐Cell Atlas of Bone Metastases Reveals Convergent Malignant Programs and Coordinated Immune Dysfunction

ABSTRACT Bone metastases (BoMs) are a major clinical challenge across cancer types, yet mechanistic insights remain limited by small cohorts and insufficient profiling depth. Here, we present a single‐cell RNA sequencing atlas of 95 BoMs, 22 healthy bone marrows (hBMs) and 129 pr...

A cfDNA fragmentomics-based liquid biopsy assay for early detection of oral cancer

Abstract Background Early detection of oral cancer improves outcomes, but remains limited by the invasiveness and low sensitivity of current screening methods. Methods This study included 342 participants (200 in the training and 142 in the validation cohorts). Plasma cfDNA under...

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

CACA guidelines for the management of adult cancer pain

Abstract Cancer pain, one of the most prevalent and distressing symptoms in cancer patients, is closely associated with cancer diagnosis, therapeutic interventions, quality of life, and survival outcomes. Effective cancer pain management requires multidisciplinary collaborative a...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Exercise-containing multimodal prehabilitation on functional outcome of patients with hepatobiliary and pancreatic cancer after surgery: a meta-analysis

Hepatobiliary and pancreatic (HBP) cancers often require complex surgeries that lead to functional decline and poor quality of life (QoL). Exercise-containing multimodal prehabilitation has gained attention as a potential strategy to enhance perioperative outcomes. This meta-anal...

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer

Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites...

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer

Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EV...

Real-world evidence of immunotherapy in older adults with advanced non-small cell lung cancer: a retrospective cohort study

Older patients are underrepresented in clinical trials of immunotherapy for driver gene-negative advanced non-small cell lung cancer (NSCLC). This study aimed to investigate real-world efficacy and safety of immunotherapy in this population. Clinical data from 649 patients aged ≥...